New drug combo shows promise for tough lung cancer
NCT ID NCT04736823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a new drug called AK112, which targets both PD1 and VEGF, combined with standard chemotherapy in 265 people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can shrink tumors and improve outcomes. Participants have stage IIIB/C or IV cancer and are in good enough health to undergo treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK112 (a drug that targets PD1 and VEGF) combined with chemotherapy drugs (pemetrexed, paclitaxel, carboplatin, docetaxel)
What this could lead to
If successful, this could lead to a new treatment option that helps shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer.
What could go wrong
This is a mid-stage trial with no control group, so results are preliminary. The combination may cause side effects like fatigue, low blood counts, or immune-related reactions, and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guanzhou, Guangdong, China